Related Experiment Video

Updated: Oct 19, 2025

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.2K

The Development of Pharmacological Therapies for Alzheimer's Disease

Ping Lin1, Junyu Sun2, Qi Cheng3,4

  • 1Department of Medical Laboratory, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Neurology and Therapy
|September 17, 2021
PubMed

Insights

This review examines recent Alzheimer's disease (AD) clinical trials, assessing therapeutic outcomes and mechanisms to guide future drug development for this progressive neurodegenerative disorder.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no current cure.
  • The growing global aged population necessitates urgent development of effective AD therapies.
  • The field of AD therapeutics is dynamic, with ongoing research and clinical trials.

Purpose of the Study:

  • To review the outcomes of recently published clinical trials for Alzheimer's disease.
  • To analyze the mechanisms of action of therapeutic agents investigated in AD trials.
  • To inform future drug development strategies and research directions in AD.

Main Methods:

  • Systematic review of published Alzheimer's disease clinical trial outcomes.
  • Analysis of therapeutic agent mechanisms of action.
  • Synthesis of findings to propose revised drug development strategies.

Main Results:

  • Some recent AD trials have demonstrated beneficial outcomes, while others showed no significant benefits.
  • Therapeutic agents target various pathways, including disease modification and symptomatic treatment.
  • Varied trial outcomes highlight the complexity of AD and the need for refined therapeutic approaches.

Conclusions:

  • Re-evaluation of Alzheimer's disease drug development strategies is crucial.
  • Future research should focus on novel mechanisms and personalized therapeutic approaches.
  • Understanding trial outcomes and mechanisms is key to advancing AD treatment.
Keywords:
Alzheimer’s diseaseClinical trialDisease-modifying therapySymptomatic treatment

More Related Videos

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

43.2K
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.4K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
302
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
763
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
45
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
119
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
241
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
33